Episode Details

FDA Advisory Panel Backs Six Peptides for Compounding Pharmacies

Phil kicks things off with an update on the torn upper horn of his lateral meniscus, sustained just before a meet he ran anyway (600 lb squat, 600 lb deadlift) rather than sit out with his son. From there the hosts pivot to a Verywell Health piece by Amber Raiken on the FDA's Pharmacy Compounding Advisory Committee recommending looser restrictions on six peptides — BPC-157, TB-500, KPV, MOTS-c, Selank, and Epitalon — while rejecting a seventh, Emoxypine, over weak human results. Mike, drawing on a recent conversation with attorney Rick Collins, explains the split between FDA researchers (mostly opposed) and the non-physician advisory panel (mostly in favor), and why compounding-pharmacy oversight could at least guarantee sterile, accurately-dosed product versus the unregulated grey market. The group works through the thin evidence base for BPC-157 — including a sham-surgery knee trial showing a large placebo effect — alongside real anecdotes, including Phil's own faster recovery after hip surgery. They also cover the money and politics behind the FDA's shift, the rise of pre-loaded peptide pens mirroring GLP-1 marketing, sermorelin's prior FDA history, grey-market use of unapproved compounds like retatrutide, and how peptides moved from underground research-chemical circles in the '90s to today's mainstream, driven largely by biohacker influencers and the normalization of GLP-1 injections — now increasingly popular with women as well as men. They close by comparing peptide-assisted recovery in elite athletes (citing Patrick Mahomes) to the old anabolic-era "impossible" recovery stories, and debate what a sane regulatory and tracking system for peptides could look like.

00:00 Welcome and Hosts

00:20 Phil's Meniscus Tear and Meet Recovery

05:02 Transition to Peptide Regulatory News

06:18 FDA Advisory Panel and the Six Peptides

12:11 BPC-157 History and Anecdotal Evidence

17:02 Network Announcements and Newsletter

19:58 FDA Politics and Compounding Pharmacy Incentives

30:07 Six Peptides List and Emoxypine Rejection

34:59 A Proposal for Peptide Regulation and Tracking

37:28 How Peptides Reached the General Public

46:48 Elite Athletes and Faster Recovery Anecdotes

50:06 Wrap and Disclaimer

Donate to the show via PayPal HERE.

You can also join Dr Mike's Insider Newsletter for more info on how to add muscle, improve your performance and body comp - all without destroying your health, go to www.ironradiodrmike.com 

Thank you!

Phil, Jerrell, Mike T, and Lonnie